Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.44 |
| ▸ | CA1 known ✓ | P00915 | 10/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 10/20 | 0.35 |
| ▸ | CA4 known ✓ | P22748 | 6/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | EYA2 | O00167 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684287 | 0.77 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL7645486 | 0.75 | CA4 (0.63) | TDP1EYA2APPACEBLM | |
| SCHEMBL873668 | 0.75 | CA4 (0.38) | LMNACA4 | |
| Edetic Acid SCHEMBL2785929 | 0.75 | CA4 (0.63) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL5309881 | 0.74 | TDP1 (0.47) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL14742967 | 0.72 | CA4 (0.59) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8818244 | 0.72 | CA4 (0.59) | TDP1EYA2APPACEBLM | |
| SCHEMBL16393916 | 0.72 | CA4 (0.46) | CA4 | |
| Pentetic Acid SCHEMBL29409454 | 0.72 | KDM4E (0.68) | TDP1EYA2APPACEBLM | |
| SCHEMBL3219620 | 0.72 | CA4 (0.44) | CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023186757-A1 | FORMULATIONS COMPOSED OF CATIONIC LIPIDS AND POLY(LACTIC-CO-GLYCOLIC ACID) FOR THE DELIVERY OF POLYNUCLEOTIDES INTO CELLS | EVONIK OPERATIONS GMBH (DE) | 2023-10-05 | — | — | WO | disclosed |
| CN-116672378-A | Compound radix puerariae, radix scutellariae and coptis chinensis soup, and method and effect thereof | 杭州师范大学附属医院 | 2023-09-01 | — | — | CN | disclosed |
| EP-3611269-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | GlaxoSmithKline Biologicals SA (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-10485761-B2 | Irradiated biodegradable polymer microparticles | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2019-11-26 | — | — | US | disclosed |
| EP-2591117-B1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-05-08 | — | — | EP | disclosed |
| US-20180280301-A1 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2018-10-04 | — | — | US | disclosed |
| EP-2440245-B1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-12-06 | — | — | EP | disclosed |
| US-9795668-B2 | Delivery of self-replicating RNA using biodegradable polymer particles | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2017-10-24 | — | — | US | disclosed |
| US-9517263-B2 | Benzonaphthyridine-containing vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-13 | — | — | US | disclosed |
| US-9393215-B2 | Nanoparticles for use in immunogenic compositions | NOVARTIS AG (CH) | 2016-07-19 | — | — | US | disclosed |
| CN-1535140-A | Microparticle compositions and methods for producing same | ϣ | 2004-10-06 | — | — | CN | disclosed |
| US-20040156913-A1 | Microparticle compositions and methods for the manufacture thereof | CHIRON CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-6753015-B2 | POLY( ALPHA -HYDROXY ACID), A POLYHYDROXY BUTYRIC ACID, A POLYCAPROLACTONE, A POLYORTHOESTER, A POLYANHYDRIDE, AND THE LIKE, AND ARE FORMED USING CATIONIC, ANIONIC, OR NONIONIC DETERGENTS | CHIRON CORPORATION | 2004-06-22 | — | — | US | disclosed |
| EP-1322292-A2 | MICROPARTICLE COMPOSITIONS AND METHODS FOR THE MANUFACTURE THEREOF | CHIRON CORPORATION (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020136776-A1 | Microparticle compositions and methods for the manufacture thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002026212-A2 | MICROPARTICLE COMPOSITIONS AND METHODS FOR THE MANUFACTURE THEREOF | CHIRON CORPORATION (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6365405-B1 | TREATING SAMPLE WITH RECOMBINANT ENYZME TO DISSOCIATE CHONDROCYTES, CULTURING IN MONOLAYER, AND CONTACTING WITH POLYOSIDIC DERIVATIVE COMPOUND IN ORDER TO DETACH ADHERING CHONDROCYTES | UNIVERSITE PIERRE ET MARIE CURIE (PARIS IV) (FR) | 2002-04-02 | — | — | US | disclosed |
| EP-1129724-A2 | Vaccines for treating colon cancer | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-0662839-A1 | VACCINES AND ANTIGENIC CONJUGATES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007530-A1 | VACCINES AND ANTIGENIC CONJUGATES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10485761-B2 | Irradiated biodegradable polymer microparticles | EXOSC9, TNF, EXOSC5 | ACE 4698/4885CA1 3198/4885CA2 4237/4885 |
| US-20180280301-A1 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES | EXOSC9, TNF, EXOSC5 | ACE 4698/4885CA1 3198/4885CA2 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.